Related Experiment Videos
Long-term outcome in children with chronic hepatitis B: a 24-year observation period
Raffaele Iorio1, Antonietta Giannattasio, Francesco Cirillo
1Department of Pediatrics, University Federico II, Naples, Italy. riorio@unina.it
Insights
Long-term outcomes for children with chronic hepatitis B virus (HBV) infection were similar whether untreated or treated with interferon-alpha. Further research is needed to determine the therapy
Area of Science:
- Pediatric Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis B virus (HBV) infection in children often presents mildly.
- Limited data exist on the long-term outcomes of untreated and interferon-treated children with HBV.
- This study examines the long-term course of HBV infection in a large pediatric cohort.
Purpose of the Study:
- To investigate the long-term clinical, biochemical, virological, and histological outcomes in children with chronic HBV infection.
- To compare the outcomes between untreated and interferon-alpha treated pediatric patients.
- To assess the impact of treatment on the natural history of chronic hepatitis B in children.
Main Methods:
- A cohort of 108 children (aged 2-18 years) with chronic HBV infection was followed for up to 24 years.
- Patients were categorized into untreated (n=67) and interferon-alpha treated (n=41) groups.
- Clinical, biochemical, virological (HBeAg, HBV DNA, anti-HBs), and histological data were collected and analyzed.
Main Results:
- After a median follow-up of 12.1 years, hepatitis B early antigen (HBeAg) loss and HBV DNA clearance occurred in 69.3% of untreated and 80% of treated patients (not statistically significant).
- Anti-HBs seroconversion was observed in 9.7% of both untreated and treated groups.
- Histological assessment revealed mild-to-moderate liver disease in 91.2% of cases; no patients developed end-stage liver disease or hepatocellular carcinoma.
Conclusions:
- Children with chronic HBV infection generally exhibit mild liver disease and remain asymptomatic.
- The long-term outcomes, including viral clearance and serological markers, did not significantly differ between treated and untreated groups.
- The definitive impact of interferon therapy on the long-term course of chronic hepatitis B in children requires further investigation.
Background:
Chronic hepatitis B seems to manifest as mild disease in children and young adults. However, data regarding the long-term course of hepatitis B in untreated and interferon-treated children are still scarce. This study investigates the long-term outcome of disease in a large series of untreated and treated children with hepatitis B virus (HBV) infection.
Methods:
Clinical, biochemical, virological, and histological features were evaluated in children (age range, 2-18 years) with chronic HBV infection who did not have concomitant chronic systemic diseases other than HBV infection and who were admitted to the liver unit in the Department of Pediatrics at University "Frederico II" (Naples, Italy) during the period 1981-2005.
Results:
One hundred eight consecutive patients observed for up to 24 years were studied. During the observation period, 67 children remained untreated, and 41 were treated with interferon-alpha. After a median period of observation of 12.1 years (range, 5-23 years), hepatitis B early antigen loss and serum HBV DNA clearance occurred in 43 untreated patients (69.3%) who were hepatitis B early antigen positive at study entry and in 33 treated children (80%; the P value is not statistically significant). In addition, 6 untreated patients (9.7%) and 4 treated patients (9.7%) became anti-HBs [corrected] positive at the end of the follow-up period. Histological assessment, evaluated for 57 children, showed mild-to-moderate disease in 91.2% of cases of HBV infection. No patient developed end-stage liver disease or hepatocellular carcinoma.
Conclusions:
Children with chronic HBV infection are symptom free, with morphologically mild liver disease. Considering that the overall long-term outcomes did not differ between treated and untreated patients, the real impact of therapy on the long-term course of HBV infection remains to be established. Additional studies are needed to confirm our conclusions.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test